Your search returned 3 results.

Results
	1.	Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. [electronic resource] by Spiegelberg, Linda Houben, Ruud Niemans, Raymon de Ruysscher, Dirk Yaromina, Ala Theys, Jan Guise, Christopher P Smaill, Jeffrey B Patterson, Adam V Lambin, Philippe Dubois, Ludwig J Publication details: Clinical and translational radiation oncology Feb 2019 In: Clinical and translational radiation oncology vol. 15 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy. [electronic resource] by Green, Laura K Syddall, Sophie P Carlin, Kendall M Bell, Glenn D Guise, Christopher P Mowday, Alexandra M Hay, Michael P Smaill, Jeffrey B Patterson, Adam V Ackerley, David F Producer: 20131105 In: Molecular cancer vol. 12 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. [electronic resource] by Jamieson, Stephen M F Gu, Yongchuan Manesh, Donya Moradi El-Hoss, Jad Jing, Duohui Mackenzie, Karen L Guise, Christopher P Foehrenbacher, Annika Pullen, Susan M Benito, Juliana Smaill, Jeffrey B Patterson, Adam V Mulaw, Medhanie A Konopleva, Marina Bohlander, Stefan K Lock, Richard B Wilson, William R Producer: 20140415 In: Biochemical pharmacology vol. 88 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)